Physician profile
Max M Benson
NPI 1093009425
$5,754.94
in general payments reported to CMS, 2019-2025
28 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $541 · 2021: $707 · 2022: $1,294 · 2023: $1,230 · 2024: $1,013 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,371.09 | 2021-2024 | Optis, Mitraclip |
| Janssen Pharmaceuticals, INC | $521.42 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $471.57 | 2020-2025 | Lifevest |
| Shockwave Medical, INC | $372.51 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $372.09 | 2019-2025 | |
| Abiomed | $356.49 | 2019-2024 | Impella |
| Amgen INC. | $295.97 | 2020-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.49 | 2020-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $241.01 | 2021-2025 | |
| Boston Scientific Corporation | $184.48 | 2020-2025 | Watchman Flx, Farapulse |
| Heartflow, INC. | $163.94 | 2023-2024 | Ffrct |
| Astrazeneca Pharmaceuticals Lp | $163.32 | 2021-2025 | Farxiga |
| Medtronic, INC. | $141.36 | 2023 | Micra |
| Janssen Scientific Affairs, LLC | $132.80 | 2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $118.65 | 2024-2025 | Assure Wcd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $95.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.93 | 2023-2024 | Camzyos |
| Philips North America LLC | $78.81 | 2020-2022 | |
| Esperion Therapeutics, INC. | $60.23 | 2020-2024 | Nexletol |
| Chiesi USA, INC. | $43.28 | 2020-2021 | |
| Novo Nordisk INC | $38.39 | 2021-2022 | |
| Phadia US INC. | $36.71 | 2022 | |
| Cvrx, INC. | $36.33 | 2023 | Barostim Neo System |
| Cardiovascular Systems INC. | $29.99 | 2019 | |
| Inspire Medical Systems, INC. | $23.71 | 2025 | Inspire |
| Impulse Dynamics (USA) INC. | $18.66 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $16.65 | 2025 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.